肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2014年
6期
419-425
,共7页
乙醛脱氢酶1%乳腺癌%分子亚型%雌激素受体%雄激素受体
乙醛脫氫酶1%乳腺癌%分子亞型%雌激素受體%雄激素受體
을철탈경매1%유선암%분자아형%자격소수체%웅격소수체
Aldehyde dehydrogenase 1%Breast cancer%Molecular subtypes%Estrogen receptor%Progesterone receptor
目的：探讨乙醛脱氢酶1（ALDH1）在乳腺癌中的表达及其与乳腺癌分子亚型和临床病理特征的相关性。方法应用免疫组织化学方法检测和比较20例乳腺癌癌旁正常乳腺组织、20例良性乳腺肿瘤组织及80例乳腺浸润性导管癌组织（Luminal A型、Luminal B型、Her-2过表达型、Basal-like型各20例）中ALDH1的表达情况，统计分析乳腺癌组织中ALDH1的表达与其分子亚型和临床病理特征的相关性。结果在20例乳腺癌癌旁正常乳腺组织及20例良性乳腺肿瘤组织中，ALDH1均呈阴性表达；80例乳腺浸润性导管癌组织中，ALDH1呈阳性表达者17例（21.25％），阳性表达率显著高于乳腺癌癌旁正常乳腺组织及良性乳腺肿瘤组织（P<0.05）；不同分子亚型乳腺癌组织中ALDH1的阳性表达率有显著性差异（P<0.05），高表达于Basal-like型及Her-2过表达型，低表达于Luminal型，且Basal-like型与Luminal型乳腺癌组织中ALDH1的阳性表达率比较有显著性差异（P<0.007），其它两两组间比较均未见显著性差异（P>0.007）。ALDH1的阳性表达与乳腺癌患者的年龄、肿瘤大小、临床分期、淋巴结转移、CK5/6、TopⅡ、Ki-67表达均无关，与ER、PR状态具有显著相关性（P<0.01）。结论乳腺癌组织中，ALDH1呈阳性表达，与乳腺癌的发生和分子分型有关，可能有助于乳腺癌的诊断、分型及预后预测。
目的：探討乙醛脫氫酶1（ALDH1）在乳腺癌中的錶達及其與乳腺癌分子亞型和臨床病理特徵的相關性。方法應用免疫組織化學方法檢測和比較20例乳腺癌癌徬正常乳腺組織、20例良性乳腺腫瘤組織及80例乳腺浸潤性導管癌組織（Luminal A型、Luminal B型、Her-2過錶達型、Basal-like型各20例）中ALDH1的錶達情況，統計分析乳腺癌組織中ALDH1的錶達與其分子亞型和臨床病理特徵的相關性。結果在20例乳腺癌癌徬正常乳腺組織及20例良性乳腺腫瘤組織中，ALDH1均呈陰性錶達；80例乳腺浸潤性導管癌組織中，ALDH1呈暘性錶達者17例（21.25％），暘性錶達率顯著高于乳腺癌癌徬正常乳腺組織及良性乳腺腫瘤組織（P<0.05）；不同分子亞型乳腺癌組織中ALDH1的暘性錶達率有顯著性差異（P<0.05），高錶達于Basal-like型及Her-2過錶達型，低錶達于Luminal型，且Basal-like型與Luminal型乳腺癌組織中ALDH1的暘性錶達率比較有顯著性差異（P<0.007），其它兩兩組間比較均未見顯著性差異（P>0.007）。ALDH1的暘性錶達與乳腺癌患者的年齡、腫瘤大小、臨床分期、淋巴結轉移、CK5/6、TopⅡ、Ki-67錶達均無關，與ER、PR狀態具有顯著相關性（P<0.01）。結論乳腺癌組織中，ALDH1呈暘性錶達，與乳腺癌的髮生和分子分型有關，可能有助于乳腺癌的診斷、分型及預後預測。
목적：탐토을철탈경매1（ALDH1）재유선암중적표체급기여유선암분자아형화림상병리특정적상관성。방법응용면역조직화학방법검측화비교20례유선암암방정상유선조직、20례량성유선종류조직급80례유선침윤성도관암조직（Luminal A형、Luminal B형、Her-2과표체형、Basal-like형각20례）중ALDH1적표체정황，통계분석유선암조직중ALDH1적표체여기분자아형화림상병리특정적상관성。결과재20례유선암암방정상유선조직급20례량성유선종류조직중，ALDH1균정음성표체；80례유선침윤성도관암조직중，ALDH1정양성표체자17례（21.25％），양성표체솔현저고우유선암암방정상유선조직급량성유선종류조직（P<0.05）；불동분자아형유선암조직중ALDH1적양성표체솔유현저성차이（P<0.05），고표체우Basal-like형급Her-2과표체형，저표체우Luminal형，차Basal-like형여Luminal형유선암조직중ALDH1적양성표체솔비교유현저성차이（P<0.007），기타량량조간비교균미견현저성차이（P>0.007）。ALDH1적양성표체여유선암환자적년령、종류대소、림상분기、림파결전이、CK5/6、TopⅡ、Ki-67표체균무관，여ER、PR상태구유현저상관성（P<0.01）。결론유선암조직중，ALDH1정양성표체，여유선암적발생화분자분형유관，가능유조우유선암적진단、분형급예후예측。
Objective To study the expression of ALDH1 in breast cancer and the relationship between ALDH1 and molecular subtypes and clinicopathological features of breast cancer. Methods Immunohemistry (IHC) was used to detect the expression of ALDH1 in 20 cases of tumor adjacent normal breast tissues, 20 cases of benign breast tumor tissues and 80 cases of invasive ductal carcinoma tissues, including Luminal A subtype, Luminal B subtype, Her-2 over-expression subtype and Basallike subtype, 20 cases of each subtype. The correlation of ALDH1 expression with the molecular subtypes and clinicopathological features of breast cancer were analyzed. Results The ALDH1 was negatively expressed in 20 cases of tumor-adjacent normal breast tissues and 20 cases of benign breast tumor tissues. 17 cases of invasive ductal carcinoma cases had positive expression of ALDH1, accounting for 21.25%. The positive expression rate of ALDH1 in carcinoma tissues was significantly higher than that of the tumor-adjacent normal breast tissues or benign breast tumor tissues (P<0.05). Moreover, the ALDH1 positive expression rate was significantly different between different molecular subtypes of breast cancer tissues (P<0.05). ALDH1 was highly expressed in Basal-like subtype and Her-2 over-expression subtype, but weakly expressed in Luminal subtype. Pairwise comparisons showed no significant difference in the ALDH1 positive expression rate between these subtype groups, except Basal-like and Luminal (P<0.007,α=0.007). In addition, the positive expression of ALDH1 had no significant correlation with the clinical and pathological features of breast cancer, includ-ing age, tumor size, clinical stage, lymph node metastasis, CK5/6, TopⅡ, Ki-67, but was significantly related to ER and PR levels (P<0.01). Conclusion ALDH1 positive phenotype only expressed in breast cancer, and was related to the development and molecular subtypes of breast cancer. It may contribute to the diagnosis, subtyping and prognostic prediction of breast cancer.
